UNSPSC 51152056: Doxacurium chloride

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M78TVM3G5Z. European Medicines Agency schedules Doxacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06380MIG. Doxacurium chloride generally arises in the molecular formula C56H78CL2N2O16.

The term DOXACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 2, no. 3, 1988, list 28.) Most nations, for tariff and trade purposes, schedule doxacurium chloride under HS 29334990 and SITC 51575. Doxacurium chloride bears US NLM identifiers UMLS ID C0114872 and NCI Concept Code C65472. SMILES: As of Q4 2014, DOXACURIUM CHLORIDE remains US FDA's Preferred Term for this commodity.

UNSPSC 51152056 Doxacurium chloride is a Commodity code that appears in state and local procurement records, but recent opportunities posted under this code do not reflect actual purchases of doxacurium chloride or related neuromuscular blocking agents. Instead, the two most recent state and local solicitations tagged to this code involve naloxone procurement and direct-to-manufacturer pharmacy programs — products and services entirely unrelated to the code's nominal scope of a specific pharmaceutical compound used in anesthesia. The mismatch suggests either a cataloging error in the posting systems or a systematic misalignment between code assignment and actual work being bought. State and local governments do purchase pharmaceutical products through competitive procurement, but the recent activity does not support a meaningful characterization of doxacurium chloride demand or issuing-body patterns under this code.

The geographic spread of recent postings includes Florida (Seminole County) and Texas (Texas Health and Human Services Commission), with no additional jurisdictions represented in the current opportunity set. The Seminole County IFB for naloxone and drug deactivation systems (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries. The Texas HHS Commission RFI (HHS0017013), posted April 3, 2026, with a same-day response deadline, was exploratory in nature and sought vendor capabilities for direct-to-manufacturer prescription fulfillment programs rather than procurement of a specific pharmaceutical product. Neither opportunity relates to doxacurium chloride procurement. Given the absence of recent solicitations aligned with the code's stated commodity, firms evaluating this code should treat it as inactive in current state and local procurement cycles and verify code assignment in future opportunity notices before investing in pursuit.